X0206 3 2018-06-27 0 0001595585 Tricida, Inc. TCDA 0001055951 ORBIMED ADVISORS LLC 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 true true 0001615374 OrbiMed Capital GP V LLC 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 true true Series A Convertible Preferred Stock Common Stock 1559716 I By OrbiMed Private Investments V, LP Series B Convertible Preferred Stock Common Stock 4300774 I By OrbiMed Private Investments V, LP Series C Convertible Preferred Stock Common Stock 3591194 I By OrbiMed Private Investments V, LP Series D Convertible Preferred Stock Common Stock 1069175 I By OrbiMed Private Investments V, LP Each of the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series C Convertible Preferred Stock and Series D Convertible Preferred Stock is convertible at any time at the option of the holder (and is automatically convertible upon closing of the Issuer's initial public offering of its Common Stock) into Common Stock at a rate of 1/3.98, for no additional consideration, and has no expiration date. These securities are held of record by OrbiMed Private Investments V, LP ("OPI V"). OrbiMed Capital GP V LLC ("GP V") is the sole general partner of OPI V, and OrbiMed Advisors LLC ("Advisors"), a registered adviser under the Investment Advisers Act of 1940, as amended, is the sole managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to have beneficial ownership over such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V. This report on Form 3 is jointly filed by GP V and Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, David P. Bonita, an employee of Advisors, to serve on the Company's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes. /s/ Jonathan T. Silverstein, member of OrbiMed Advisors LLC 2018-06-27 /s/ Sven H. Borho, member of OrbiMed Advisors LLC 2018-06-27 /s/ Carl L. Gordon, member of OrbiMed Advisors LLC 2018-06-27